Fabio Cohen Tucci
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$9.4MFederal grants as PI16 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
16 awards · $9.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 11, 2024 | NIH | SBIR Phase II Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | $1.0M | Epigen Biosciences, Inc. |
| Aug 23, 2023 | NIH | SBIR Phase II Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | $972K | Epigen Biosciences, Inc. |
| May 31, 2023 | NIH | SBIR Phase I New Therapy for the Treatment of Primary Biliary Cholangitis. | $448K | Epigen Biosciences, Inc. |
| Apr 20, 2022 | NIH | SBIR Phase II Novel therapy for Fragile X syndrome | $1.2M | Epigen Biosciences, Inc. |
| Sep 20, 2021 | NIH | SBIR Phase I Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH | $397K | Epigen Biosciences, Inc. |
| Aug 20, 2021 | NIH | SBIR Phase II Administrative supplement for Novel therapy for Fragile X syndrome | $50K | Epigen Biosciences, Inc. |
| Apr 12, 2021 | NIH | SBIR Phase II Novel therapy for Fragile X syndrome | $999K | Epigen Biosciences, Inc. |
| Jul 30, 2020 | NIH | SBIR Phase I Assessment of a selective kinase inhibitor in pre-clinical models of NASH | $375K | Epigen Biosciences, Inc. |
| Jun 2, 2020 | NIH | SBIR Phase II Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | $1000K | Epigen Biosciences, Inc. |
| Jul 25, 2019 | NIH | SBIR Phase II Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | $999K | Epigen Biosciences, Inc. |
| Sep 5, 2018 | NIH | SBIR Phase I Assessment of LPA1R antagonists in animal models of NASH | $299K | Epigen Biosciences, Inc. |
| Jun 20, 2018 | NIH | STTR Phase I Novel therapy for Fragile X syndrome | $318K | Epigen Biosciences, Inc. |
| Sep 26, 2017 | NIH | STTR Phase I Novel therapy for Fragile X syndrome | $117K | Epigen Biosciences, Inc. |
| Sep 14, 2017 | NIH | STTR Phase I Novel therapy for Fragile X syndrome | $400K | Epigen Biosciences, Inc. |
| Sep 1, 2016 | NIH | SBIR Phase II Development of novel agents for the treatment of renal fibrosis adminstrative supplement | $2K | Epigen Biosciences, Inc. |
| Aug 26, 2015 | NIH | SBIR Phase II Development of novel agents for the treatment of renal fibrosis | $835K | Epigen Biosciences, Inc. |
Peer ranks
Federal funding#75
Awards as PI#37
Patents#273
Companies
- Epigen Biosciences, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.